Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance
Abstract
:1. Introduction
2. Candida albicans: Morphology and Virulence
3. Immune Response and Conventional Treatment Therapies
4. Histatin 5: New Antifungal Therapies
5. Metal Complexes and Hst5 as a Strategy to Fight C. albicans
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Akpan, A.; Morgan, R. Oral candidiasis. Postgrad. Med. J. 2002, 78, 455–459. [Google Scholar] [CrossRef]
- Santos, G.C.O.; Vasconcelos, C.C.; Lopes, A.J.O.; Cartágenes, M.S.d.S.; Filho, A.K.D.B.; do Nascimento, F.R.F.; Ramos, R.M.; Pires, E.R.R.B.; Andrade, M.S.; Rocha, F.M.G.; et al. Candida infections and therapeutic strategies: Mechanisms of action for traditional and alternative agents. Front. Microbiol. 2018, 9, 1351. [Google Scholar] [CrossRef] [PubMed]
- Sardi, J.C.O.; Scorzoni, L.; Bernardi, T.; Fusco-Almeida, A.M.; Giannini, M.M. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J. Med. Microbiol. 2013, 62, 10–24. [Google Scholar] [CrossRef]
- Vandeputte, P.; Ferrari, S.; Coste, A.T. Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol. 2012, 2012, 713687. [Google Scholar] [CrossRef] [PubMed]
- Pereira, R.; Fontenelle, R.O.d.S.; de Brito, E.H.S.; de Morais, S.M. Biofilm of Candida albicans: Formation, regulation and resistance. J. Appl. Microbiol. 2021, 131, 11–22. [Google Scholar] [CrossRef]
- Tuite, A.; Mullick, A.; Gros, P. Genetic analysis of innate immunity in resistance to Candida albicans. Genes Immun. 2004, 5, 576–587. [Google Scholar] [CrossRef] [Green Version]
- Dadgostar, P. Antimicrobial resistance: Implications and costs. Infect. Drug Resist. 2019, 12, 3903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roope, L.S.J.; Smith, R.D.; Pouwels, K.B.; Buchanan, J.; Abel, L.; Eibich, P.; Butler, C.C.; Tan, P.S.; Walker, A.S.; Robotham, J.V.; et al. The challenge of antimicrobial resistance: What economics can contribute. Science 2019, 364, 6435. [Google Scholar] [CrossRef]
- Laxminarayan, R.; Matsoso, P.; Pant, S.; Brower, C.; Røttingen, J.A.; Klugman, K.; Davies, S. Access to effective antimicrobials: A worldwide challenge. Lancet 2016, 387, 168–175. [Google Scholar] [CrossRef]
- Prestinaci, F.; Pezzotti, P.; Pantosti, A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health 2015, 109, 309–318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. 19 May 2016. Available online: https://apo.org.au/node/63983 (accessed on 15 June 2021).
- Laxminarayan, R.; Sridhar, D.; Blaser, M.; Wang, M.; Woolhouse, M. Achieving global targets for antimicrobial resistance. Science 2016, 353, 874–875. [Google Scholar] [CrossRef] [Green Version]
- WHO. Clinical Management of COVID-19 Patients: Living Guidance. 25 January 2021. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (accessed on 22 June 2021).
- Bhatt, K.; Agolli, A.; Patel, M.H.; Garimella, R.; Devi, M.; Garcia, E.; Amin, H.; Domingue, C.; Del Castillo, R.G.; Sanchez-Gonzalez, M. High mortality co-infections of COVID-19 patients: Mucormycosis and other fungal infections. Discoveries 2021, 9, e126. [Google Scholar] [CrossRef] [PubMed]
- Salehi, M.; Ahmadikia, K.; Badali, H.; Khodavaisy, S. Opportunistic fungal infections in the epidemic area of COVID-19: A clinical and diagnostic perspective from Iran. Mycopathologia 2020, 185, 607–611. [Google Scholar] [CrossRef]
- Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-resistant Candida auris infections in critically Ill coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis. 2020, 26, 2694. [Google Scholar] [CrossRef] [PubMed]
- Mastrangelo, A.; Germinario, B.N.; Ferrante, M.; Frangi, C.; Voti, R.L.; Muccini, C.; Ripa, M. Candidemia in COVID-19 patients: Incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020. [Google Scholar] [CrossRef]
- Reid, G.; Lynch III, J.P.; Fishbein, M.C.; Clark, N.M. Mucormycosis. Semin. Respir. Crit. Care Med. Thieme Med. Publ. 2020, 41, 99–114. [Google Scholar] [CrossRef] [PubMed]
- Al-Hatmi, A.M.S.; Mohsin, J.; Al-Huraizi, A.; Khamis, F. COVID-19 associated invasive candidiasis. J. Infect. 2021, 82, e45–e46. [Google Scholar] [CrossRef]
- Szarpak, L.; Chirico, F.; Pruc, M.; Szarpak, L.; Dzieciatkowski, T.; Rafique, Z. Mucormycosis—A serious threat in the COVID-19 pandemic? J. Infect. 2021, 83, 237–279. [Google Scholar] [CrossRef]
- Garg, D.; Muthu, V.; Sehgal, I.S.; Ramachandran, R.; Kaur, H.; Bhalla, A.; Puri, G.D.; Chakrabarti, A.; Agarwal, R. Coronavirus disease (COVID-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021, 186, 289–298. [Google Scholar] [CrossRef]
- Karimi-Galougahi, M.; Arastou, S.; Haseli, S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int. Forum. Allergy Rhinol. 2021, 11, 1029. [Google Scholar] [CrossRef]
- Werthman-Ehrenreich, A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med. 2021, 42, 264. [Google Scholar] [CrossRef]
- Singh, A.K.; Singh, R.; Joshi, S.R.; Misra, A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 102146. [Google Scholar] [CrossRef]
- Prakash, H.; Chakrabarti, A. Epidemiology of mucormycosis in India. Microorganisms 2021, 9, 523. [Google Scholar] [CrossRef]
- Höfs, S.; Mogavero, S.; Hube, B. Interaction of Candida albicans with host cells: Virulence factors, host defense, escape strategies, and the microbiota. J. Microbiol. 2016, 54, 149–169. [Google Scholar] [CrossRef] [PubMed]
- Lansbury, L.; Lim, B.; Baskaran, V.; Lim, W.S. Co-infections in people with COVID-19: A systematic review and meta-analysis. J. Infect. 2020, 81, 266–275. [Google Scholar] [CrossRef] [PubMed]
- Rawson, T.M.; Wilson, R.C.; Holmes, A. Understanding the role of bacterial and fungal infection in COVID-19. Clin. Microbiol. Infect. 2021, 27, 9. [Google Scholar] [CrossRef] [PubMed]
- Rawson, T.M.; Moore, L.S.P.; Castro-Sanchez, E.; Charani, E.; Davies, F.; Satta, G.; Ellington, M.J.; Holmes, A.H. COVID-19 and the potential long-term impact on antimicrobial resistance. J. Antimicrob. Chemother. 2020, 75, 1681–1684. [Google Scholar] [CrossRef] [PubMed]
- World Health Assembly. Global Action Plan on Antimicrobial Resistance. 2015. Available online: https://www.who.int/publications/i/item/9789241509763 (accessed on 3 July 2021).
- Colombo, A.L.; Nucci, M.; Park, B.J.; Noueér, S.A.; Arthington-Skaggs, B.; da Matta, D.A.; Warnock, D.; Morgan, J. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 2006, 44, 2816–2823. [Google Scholar] [CrossRef] [Green Version]
- Lamoth, F.; Lockhart, S.R.; Berkow, E.L.; Calandra, T. Changes in the epidemiological landscape of invasive candidiasis. J. Antimicrob. Chemother. 2018, 73, i4–i13. [Google Scholar] [CrossRef] [Green Version]
- Dadar, M.; Tiwari, R.; Karthik, K.; Chakraborty, S.; Shahali, Y.; Dhama, K. Candida albicans-biology, molecular characterization, pathogenicity, and advances in diagnosis and control—An update. Microb. Pathog. 2018, 117, 128–138. [Google Scholar] [CrossRef]
- Vila, T.; Romo, J.A.; Pierce, C.G.; McHardy, S.F.; Saville, S.P.; Lopez-Ribot, J.L. Targeting Candida albicans filamentation for antifungal drug development. Virulence 2017, 8, 150–158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Puri, S.; Friedman, J.; Saraswat, D.; Kumar, R.; Li, R.; Ruszaj, D.; Edgerton, M. Candida albicans Shed Msb2 and host mucins affect the candidacidal activity of salivary Hst 5. Pathogens 2015, 4, 752–763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lu, J.; Xu, H.; Xia, J.; Ma, J.; Xu, J.; Li, Y.; Feng, J. D-and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics. Front. Microbiol. 2020, 11, 563030. [Google Scholar] [CrossRef]
- Cheng, K.T.; Wu, C.; Yip, B.; Chih, Y.; Peng, K.; Hsu, S.; Yu, H.; Cheng, J. The interactions between the antimicrobial peptide P-113 and living candida albicans cells shed light on mechanisms of antifungal activity and resistance. Int. J. Mol. Sci. 2020, 21, 2654. [Google Scholar] [CrossRef] [Green Version]
- Tati, S.; Li, R.; Puri, S.; Kumar, R.; Davidow, P.; Edgerton, M. Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis. Antimicrob. Agents Chemother. 2014, 58, 756–766. [Google Scholar] [CrossRef] [Green Version]
- Seo, M.D.; Won, H.S.; Kim, J.H.; Mishig-Ochir, T.; Lee, B.J. Antimicrobial peptides for therapeutic applications: A review. Molecules 2012, 17, 12276–12286. [Google Scholar] [CrossRef] [Green Version]
- Rothstein, D.M.; Spacciapoli, P.; Tran, L.T.; Xu, T.; Roberts, F.D.; Serra, M.D.; Buxton, D.K.; Oppenheim, F.G.; Friden, P. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob. Agents Chemother. 2001, 45, 1367–1373. [Google Scholar] [CrossRef] [Green Version]
- Melino, S.; Gallo, M.; Trotta, E.; Mondello, F.; Paci, M.; Petruzzelli, R. Metal-binding and nuclease activity of an antimicrobial peptide analogue of the salivary histatin 5. Biochemistry 2006, 45, 15373–15383. [Google Scholar] [CrossRef] [PubMed]
- Melino, S.; Rufini, S.; Sette, M.; Morero, R.; Grottesi, A.; Paci, M.; Petruzzelli, R. Zn2+ ions selectively induce antimicrobial salivary peptide histatin-5 to fuse negatively charged vesicles. Identification and characterization of a zinc-binding motif present in the functional domain. Biochemistry 1999, 38, 9626–9633. [Google Scholar] [CrossRef]
- Moffa, E.B.; Mussi, M.; Xiao, Y.; Garrido, S.S.; Machado, M.A.; Giampaolo, E.T.; Siqueira, W.L. Histatin 5 inhibits adhesion of C. albicans to reconstructed human oral epithelium. Front. Microbiol. 2015, 6, 885. [Google Scholar] [CrossRef] [Green Version]
- Gulati, M.; Nobile, C.J. Candida albicans biofilms: Development, regulation, and molecular mechanisms. Microbes Infect. 2016, 18, 310–321. [Google Scholar] [CrossRef] [Green Version]
- Jacobsen, I.D.; Wilson, D.; Wächtler, B.; Brunke, S.; Naglik, J.R.; Hube, B. Candida albicans dimorphism as a therapeutic target. Expert Rev. Anti-Infect. Ther. 2012, 10, 85–93. [Google Scholar] [CrossRef] [Green Version]
- Gow, N.A.R.; Hube, B. Importance of the Candida albicans cell wall during commensalism and infection. Curr. Opin. Microbiol. 2012, 15, 406–412. [Google Scholar] [CrossRef] [Green Version]
- Chen, H.; Zhou, X.; Ren, B.; Cheng, L. The regulation of hyphae growth in Candida albicans. Virulence 2020, 11, 337–348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, A.J.P.; Brown, G.D.; Netea, M.G.; Gow, N.A. Metabolism impacts upon Candida immunogenicity and pathogenicity at multiple levels. Trends Microbiol. 2014, 22, 614–622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selmecki, A.; Forche, A.; Berman, J. Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryot. Cell 2010, 9, 991–1008. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wächtler, B.; Citiulo, F.; Jablonowski, N.; Förster, S.; Dalle, F.; Schaller, M.; Wilson, D.; Hube, B. Candida albicans-epithelial interactions: Dissecting the roles of active penetration, induced endocytosis and host factors on the infection process. PLoS ONE 2012, 7, e36952. [Google Scholar] [CrossRef] [Green Version]
- Bojang, E.; Ghuman, H.; Kumwenda, P.; Hall, R.A. Immune Sensing of Candida albicans. J. Fungi 2021, 7, 119. [Google Scholar] [CrossRef] [PubMed]
- Wilson, D.; Naglik, J.R.; Hube, B. The missing link between Candida albicans hyphal morphogenesis and host cell damage. PLoS Pathog. 2016, 12, e1005867. [Google Scholar] [CrossRef] [Green Version]
- Zhu, W.; Filler, S.G. Interactions of Candida albicans with epithelial cells. Cell. Microbiol. 2010, 12, 273–282. [Google Scholar] [CrossRef] [Green Version]
- Naglik, J.R.; Moyes, D.L.; Wächtler, B.; Hube, B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect. 2011, 13, 963–976. [Google Scholar] [CrossRef] [Green Version]
- Clayton, P.T. Inherited disorders of transition metal metabolism: An update. J. Inherit. Metab. Dis. 2017, 40, 519–529. [Google Scholar] [CrossRef]
- Bailão, E.F.L.C.; Parente, A.F.A.; Parente, J.A.; Silva-Bailão, M.G.; Castro, K.P.; Kmetzsch, L.; Staats, C.C.; Schrank, A.; Vainstein, M.H.; Borges, C.L.; et al. Metal acquisition and homeostasis in fungi. Curr. Fungal Infect. Rep. 2012, 6, 257–266. [Google Scholar] [CrossRef]
- Haas, H.; Eisendle, M.; Turgeon, B.G. Siderophores in fungal physiology and virulence. Annu. Rev. Phytopathol. 2008, 46, 149–187. [Google Scholar] [CrossRef]
- Chakraborty, T.; Tóth, Z.; Tóth, R.; Vágvölgyi, C.; Gácser, A. Iron Metabolism, Pseudohypha Production, and Biofilm Formation through a Multicopper Oxidase in the Human-Pathogenic Fungus Candida parapsilosis. Msphere 2020, 5, e00227-20. [Google Scholar] [CrossRef] [PubMed]
- Khemiri, I.; Tebbji, F.; Sellam, A. Transcriptome analysis uncovers a link between copper metabolism, and both fungal fitness and antifungal sensitivity in the opportunistic yeast Candida albicans. Front. Microbiol. 2020, 11, 935. [Google Scholar] [CrossRef]
- Mackie, J.; Szabo, E.K.; Urgast, D.S.; Ballou, E.R.; Childers, D.S.; MacCallum, D.M.; Feldmann, J.; Brown, A.J.P. Host-imposed copper poisoning impacts fungal micronutrient acquisition during systemic Candida albicans infections. PLoS ONE 2016, 11, e0158683. [Google Scholar] [CrossRef] [Green Version]
- Staats, C.C.; Kmetzsch, L.; Schrank, A.; Vainstein, M.H. Fungal zinc metabolism and its connections to virulence. Front. Cell. Infect. Microbiol. 2013, 3, 65. [Google Scholar] [CrossRef] [Green Version]
- Citiulo, F.; Jacobsen, I.D.; Miramón, P.; Schild, L.; Brunke, S.; Zipfel, P.; Brock, M.; Hube, B.; Wilson, D. Candida albicans scavenges host zinc via Pra1 during endothelial invasion. PLoS Pathog. 2012, 8, e1002777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zipfel, P.F. Complement and immune defense: From innate immunity to human diseases. Immunol. Lett. 2009, 126, 1–7. [Google Scholar] [CrossRef]
- Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 2017, 17, e383–e392. [Google Scholar] [CrossRef]
- Spampinato, C.; Leonardi, D. Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. BioMed Res. Int. 2013, 2013, 204237. [Google Scholar] [CrossRef] [Green Version]
- Sanguinetti, M.; Posteraro, B.; Lass-Flörl, C. Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses 2015, 58, 2–13. [Google Scholar] [CrossRef]
- Cowen, L.E.; Steinbach, W.J. Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance. Eukaryot. Cell 2008, 7, 747–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Y.; Puumala, E.; Robbins, N.; Cowen, L.E. Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond. Chem. Rev. 2020, 121, 3390–3411. [Google Scholar] [CrossRef] [PubMed]
- Noël, T. The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. J. Mycol. Med. 2012, 22, 173–178. [Google Scholar] [CrossRef] [PubMed]
- Niimi, M.; Firth, N.A.; Cannon, R.D. Antifungal drug resistance of oral fungi. Odontology 2010, 98, 15–25. [Google Scholar] [CrossRef]
- Moghaddam-Taaheri, P.; Leissa, J.A.; Eppler, H.B.; Jewell, C.M.; Karlsson, A.J. Histatin 5 variant reduces Candida albicans biofilm viability and inhibits biofilm formation. Fungal Genet. Biol. 2021, 149, 103529. [Google Scholar] [CrossRef] [PubMed]
- Bullock, C.B.; Mcnabb, D.S.; Pinto, I. Whole-genome approach to understanding the mechanism of action of a histatin 5-derived peptide. Antimicrob. Agents Chemother. 2020, 64, e01698-19. [Google Scholar] [CrossRef] [PubMed]
- Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389–395. [Google Scholar] [CrossRef]
- Teixeira, V.; Feio, M.J.; Bastos, M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 2012, 51, 149–177. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.; Huang, J.; Chen, Y. Alpha-helical cationic antimicrobial peptides: Relationships of structure and function. Protein Cell 2010, 1, 143–152. [Google Scholar] [CrossRef] [PubMed]
- Shah, D.; Son, K.N.; Kalmodia, S.; Lee, B.S.; Ali, M.; Balasubramaniam, A.; Shukla, D.; Aakalu, V.K. Wound healing properties of histatin-5 and identification of a functional domain required for histatin-5-induced cell migration. Mol. Ther. Methods Clin. Dev. 2020, 17, 709–716. [Google Scholar] [CrossRef]
- Helmerhorst, E.J.; Hof, W.V.; Breeuwer, P.; Troxler, R.F.; Amerongen, A.V.N.; Oppenheim, F.G. Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation. J. Biol. Chem. 2001, 276, 5643–5649. [Google Scholar] [CrossRef] [Green Version]
- De Smet, K.; Contreras, R. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnol. Lett. 2005, 27, 1337–1347. [Google Scholar] [CrossRef]
- Calderone, R.A.; Clancy, C.J. Candida and Candidiasis, 2nd ed.; American Society for Microbiology Press: Washington, DC, USA, 2011. [Google Scholar]
- Kavanagh, K.; Dowd, S. Histatins: Antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. 2004, 56, 285–289. [Google Scholar] [CrossRef] [Green Version]
- Puri, S.; Edgerton, M. How does it kill?: Understanding the candidacidal mechanism of salivary histatin 5. Eukaryot. Cell 2014, 13, 958–964. [Google Scholar] [CrossRef] [Green Version]
- Helmerhorst, E.J.; Alagl, A.S.; Siqueira, W.L.; Oppenheim, F.G. Oral fluid proteolytic effects on histatin 5 structure and function. Arch. Oral Biol. 2006, 51, 1061–1070. [Google Scholar] [CrossRef] [PubMed]
- Puri, S.; Li, R.; Ruszaj, D.; Tati, S.; Edgerton, M. Iron binding modulates candidacidal properties of salivary histatin 5. J. Dent. Res. 2015, 94, 201–208. [Google Scholar] [CrossRef] [Green Version]
- Hampe, I.A.I.; Friedman, J.; Edgerton, M.; Morschhäuser, J. An acquired mechanism of antifungal drug resistance simultaneously enables Candida albicans to escape from intrinsic host defenses. PLoS Pathog. 2017, 13, e1006655. [Google Scholar] [CrossRef] [Green Version]
- Bochenska, O.; Rapala-Kozik, M.; Wolak, N.; Aoki, W.; Ueda, M.; Kozik, A. The action of ten secreted aspartic proteases of pathogenic yeast Candida albicans on major human salivary antimicrobial peptide, histatin 5. Acta Biochim. Pol. 2016, 63, 403–410. [Google Scholar] [CrossRef] [Green Version]
- Szafranski-Schneider, E.; Swidergall, M.; Cottier, F.; Tielker, D.; Román, E.; Pla, J.; Ernst, J.F. Msb2 shedding protects Candida albicans against antimicrobial peptides. PLoS Pathog 2012, 8, e1002501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, B.; Qin, X.; Zhou, M.; Tian, T.; Sun, Y.; Li, S.; Xiao, D.; Cai, X. Tetrahedral DNA nanostructure improves transport efficiency and anti-fungal effect of histatin 5 against Candida albicans. Cell Prolif. 2021, 54, e13020. [Google Scholar] [CrossRef] [PubMed]
- Meiller, T.F.; Hube, B.; Schild, L.; Shirtliff, M.E.; Scheper, M.A.; Winkler, R.; Ton, A.; Jabra-Rizk, M.A. A novel immune evasion strategy of Candida albicans: Proteolytic cleavage of a salivary antimicrobial peptide. PLoS ONE 2009, 4, e5039. [Google Scholar] [CrossRef] [Green Version]
- Ikonomova, S.P.; Moghaddam-Taaheri, P.; Wang, Y.; Doolin, M.T.; Stroka, K.M.; Hube, B.; Karlsson, A.J. Effects of histatin 5 modifications on antifungal activity and kinetics of proteolysis. Protein Sci. 2020, 29, 480–493. [Google Scholar] [CrossRef]
- Han, J.; Jyoti, M.A.; Song, H.Y.; Jang, W.S. Antifungal activity and action mechanism of histatin 5-halocidin hybrid peptides against Candida ssp. PLoS ONE 2016, 11, e0150196. [Google Scholar] [CrossRef] [Green Version]
- Di Natale, C.; De Benedictis, I.; De Benedictis, A.; Marasco, D. Metal–Peptide Complexes as Promising Antibiotics to Fight Emerging Drug Resistance: New Perspectives in Tuberculosis. Antibiotics 2020, 9, 337. [Google Scholar] [CrossRef]
- Conklin, S.E.; Bridgman, E.C.; Su, Q.; Riggs-Gelasco, P.; Haas, K.L.; Franz, K.J. Specific histidine residues confer histatin peptides with copper-dependent activity against Candida albicans. Biochemistry 2017, 56, 4244–4255. [Google Scholar] [CrossRef] [PubMed]
- Gusman, H.; Lendenmann, U.; Grogan, J.; Troxler, R.F.; Oppenheim, F.G. Is salivary histatin 5 a metallopeptide? Biochim. Biophys. Acta (BBA) Protein Struct. Mol. Enzymol. 2001, 1545, 86–95. [Google Scholar] [CrossRef]
- Brewer, D.; Lajoie, G. Evaluation of the metal binding properties of the histidine-rich antimicrobial peptides histatin 3 and 5 by electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 1736–1745. [Google Scholar] [CrossRef]
- Melino, S.; Santone, C.; Di Nardo, P.; Sarkar, B. Histatins: Salivary peptides with copper (II)-and zinc (II)-binding motifs: Perspectives for biomedical applications. FEBS J. 2014, 281, 657–672. [Google Scholar] [CrossRef]
- McCaslin, T.G.; Pagba, C.V.; Yohannan, J.; Barry, B.A. Specific metallo-protein interactions and antimicrobial activity in Histatin-5, an intrinsically disordered salivary peptide. Sci. Rep. 2019, 9, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rae, T.D.; Schmidt, P.J.; Pufahl, R.A.; Culotta, V.C.; O’halloran, T.V. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 1999, 284, 805–808. [Google Scholar] [CrossRef] [Green Version]
- Frączyk, T. Phosphorylation Impacts Cu (II) Binding by ATCUN Motifs. Inorg. Chem. 2021, 60, 8447–8450. [Google Scholar] [CrossRef] [PubMed]
- Norris, H.L.; Kumar, R.; Ong, C.Y.; Xu, D.; Edgerton, M. Zinc binding by histatin 5 promotes fungicidal membrane disruption in C. albicans and C. glabrata. J. Fungi 2020, 6, 124. [Google Scholar] [CrossRef]
- Kurowska, E.; Bonna, A.; Goch, G.; Bal, W. Salivary histatin-5, a physiologically relevant ligand for Ni (II) ions. J. Inorg. Biochem. 2011, 105, 1220–1225. [Google Scholar] [CrossRef] [PubMed]
- Dong, J.; Vylkova, S.; Li, X.S.; Edgerton, M. Calcium blocks fungicidal activity of human salivary histatin 5 through disruption of binding with Candida albicans. J. Dent. Res. 2003, 82, 748–752. [Google Scholar] [CrossRef] [PubMed]
Metal | Coordination Site in Hst5 | Complexation Effects | Reference |
---|---|---|---|
Copper | ATCUN | Improves peptide stability Enhances antifungal activity Raises ROS liberation Enhances the fungus nutritional hunger | [92] [93] [95] |
Zinc | HEXXH | Improves peptide’s functional domain stability Improves the stability of peptide’s α-helical conformation Destabilizes fungus lipidic bilayer Promotes fungus acid nucleic hydrolysis Little protection on peptide proteolytic degradation | [42] [83] [95] |
Nickel | ATCUN | Improves the stability of peptide’s α-helical conformation Facilitates the peptides bond with fungus DNA | [41] [100] |
Iron | uncertain | Minimizes drastically antifungal activity Enhances the fungus nutritional hunger Affects the peptides interaction with the fungal cell wall Interferes on iron cellular metabolism, leading fungal mitochondria to death | [83] [92] |
Calcium | uncertain | Inhibits antifungal activity Suppresses ATP efflux Interrupts the bond between peptide and fungus cell | [101] |
Magnesium | uncertain | Minimizes antifungal activity Decreases ATP efflux | [101] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zolin, G.V.S.; Fonseca, F.H.d.; Zambom, C.R.; Garrido, S.S. Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance. Biomolecules 2021, 11, 1209. https://doi.org/10.3390/biom11081209
Zolin GVS, Fonseca FHd, Zambom CR, Garrido SS. Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance. Biomolecules. 2021; 11(8):1209. https://doi.org/10.3390/biom11081209
Chicago/Turabian StyleZolin, Gabriela Vieira Silva, Fauller Henrique da Fonseca, Carolina Reis Zambom, and Saulo Santesso Garrido. 2021. "Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance" Biomolecules 11, no. 8: 1209. https://doi.org/10.3390/biom11081209
APA StyleZolin, G. V. S., Fonseca, F. H. d., Zambom, C. R., & Garrido, S. S. (2021). Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance. Biomolecules, 11(8), 1209. https://doi.org/10.3390/biom11081209